Iranian Heart Journal

Iranian Heart Journal

Serum-Soluble ST2 (sST2) and NT-proBNP Levels in Children With Pulmonary Arterial Hypertension

Document Type : Original Article

Authors
Merve Kaya Durmuş 1
Cemşit Karakurt 2
Çağatay Taşkapan 3
Mehmet Öncül 2
Özlem Elkıran 2
Nilüfer Bulut 3
Harika Gözükara Bağ 4
1 Inonu University, Faculty of Medicine, Department of Pediatrics, Malatya, Turkey.
2 Inonu University, Faculty of Medicine, Department of Pediatric Cardiology, Malatya, Turkey.
3 Inonu University, Faculty of Medicine, Department of Biochemistry, Malatya, Turkey.
4 Inonu University, Faculty of Medicine, Department of Biostatistics, Malatya, Turkey.
Abstract
Background: Soluble ST2 (sST2) is a member of the interleukin-1 receptor family and is considered a novel biomarker of inflammation, fibrosis, and cardiac stress. Additionally, sST2 is accepted by guidelines as a measure of risk stratification in patients with heart failure.
 
Methods: Our study enrolled 53 subjects: 23 patients who were followed up for pulmonary arterial hypertension (PAH) and were prescribed different medications and 30 healthy children admitted to the pediatric cardiology outpatient clinic with chest pain or innocent murmurs as the control group. The plasma concentration of NT-proBNP was analyzed via the electrochemiluminescence method, and the sST2 level was analyzed via the ELISA method.
 
Results: The mean age was 13.9 years (5.5–18 y) in the case group and 9.6 years (3–17 y) in the control group. The mean NT-proBNP level was significantly higher in the patient group than in the control group (763.73±2432.67 pg/mL vs 51.71± 30.08 pg/mL; P<0.01). The mean sST2 level was 1469.26±510.9 pg/mL in the patient group and 1151.30±655.99 pg/mL in the control group (P>0.05).
 
Conclusions: Our results suggest that sST2 could be a significant indicator of right heart failure and cardiovascular mortality in children, as well as a novel biomarker of PAH. However, we found that the serum sST2 level was not as useful as the serum NT-proBNP level in this regard. Further studies with larger patient series are needed to evaluate sST2 as a biomarker in patients with PAH. (Iranian Heart Journal 2022; 23(4): 46-51)
Keywords
Pulmonary hypertension
Biomarker
NT-proBNP
Soluble ST2
  1. Wang TJ, Wollert KC, Larson MG, Coglianese E, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 25(12):1596-604.
  2. Sanada, S., Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signalling system. J Clin Invest, 2007. 117(6): 1538-49.
  3. Pascual-Figal, D.A, Januzzi J.L. The biology of ST2: The international ST2 consensus panel. Am J Cardiol 2015; 15(7 Suppl): 3B-7B.
  4. Schmitz, J., Owyang A, Oldham E et al., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005. 23(5): 479-490.
  5. Agoston-Coldea L, Lupu S, Hicea S, et al. Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomark Med. 2014; 8:11–18.
  6. Zheng, Y.G.; Yang, T.; He, J.G.; Chen, G.; Liu, Z.H.; Xiong, C.M.; Gu, Q.; Ni, X.H.; Zhao, Z.H. Plasma solubleST levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin. Cardiol. 2014, 37, 365–370.
  7. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018.
  8. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:42-50.
  9. Barst RJ. Diagnosis and assessment of pulmonary. Hypertension in infants and Prog Pediatr Cardiol 2001; 12:279-88.
  10. Haworth SG. The management of children with congenital heart disease. In: Beghetti M, Barst RJ, Naeije R, Rubin LJ (eds). Pulmonary Arterial Hypertension Related to Congenital Heart Disease, 2006, Elsevier, New York, pp 129-41.
  11. Duffels MGJ, Engelfriet PM, Berger RMF, van Loon RLE, Hoendermis E, Vriend JWJ, van der Velde ET, Bresser P, Mulder BJM. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int. J Cardiol 2007; 120:198 –204.
  12. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. European Respiratory Journal. 2008 32: 503-512.
  13. Carlomagno G, Messalli G, Melillo RM, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol. 2013; 168:1545–1547.
  14. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 78S-92S
  15. Chida A, Sato H, Shintani M, et al. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Circ J. 2014; 78:436–442.
Iranian Heart Journal
Volume 23, Issue 4
Autumn 2022
Pages 46-51